HIV Vaccines

Second IAVI-Sponsored Vaccine For Africa Enters Human Trials In U.K.

Published in AIDS Weekly, April 9th, 2001

The second International AIDS Vaccine Initiative (IAVI-) sponsored preventive HIV vaccine designed specifically for Africa entered human trials on March 14, 2001, in the U.K. with the inoculation of five volunteers.

Testing of the vaccine will begin later in Kenya.

The MVA, or modified vaccinia Ankara, vaccine is the first of its kind to be tested in humans. Derived from a virus used in smallpox immunization, the vaccine aims to stimulate the production of a certain kind of immune cell that kills other cells infected with HIV. The vaccine is attenuated through genetic modification so it cannot cause infection with either HIV or pox...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2001-04-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry